Dexcom received FDA clearance for people over the age of 18 years old in the U.S. in April for the 15-day version of its latest-generation sensor. Last month, the company announced its plans for a December launch for G7 15 Day.
At launch, the company said its newest CGM pairs with the iLet Bionic Pancreas from Beta Bionics in addition to Insulet’s Omnipod 5. Dexcom has work underway with Tandem Diabetes Care to finalize integration for G7 15 Day with its pumps as well.
On LinkedIn, Beta Bionics shared the full compatibility of the systems as G7 15 Day officially hit the market this week.
“We’re excited to share that the new Dexcom G7 15 Day sensor is now available — and the iLet Bionic Pancreas is fully compatible at launch!” Beta Bionics wrote.
The company said the launch requires no changes from iLet users. When pairing a new sensor, they can simply choose “Dexcom G7” as usual on the iLet. The device automatically knows that the sensor is a G7 15 Day CGM. Beta Bionics said the integrated offering now enables longer wear-time of up to 15.5 days, plus fewer warm-ups and sensor changes.
G7 15 Day is now available through medical distributors only. The company plans to ship sensors to pharmacies in early January 2026.
Beta Bionics and Dexcom are two of the largest diabetes tech companies in the world. Read more about them in our free Diabetes Technology Special Report.
Visit here to purchase our Medtech Market Special Report on CGMs.
G7 15 Day, Dexcom’s latest-generation CGM, the longest-lasting wearable CGM, according to the company. The offering delivers several features of the existing G7 platform. That includes a waterproof sensor, connectivity to the Apple Watch, plus automated activity, simplified meal and new medication logging. Its 12-hour grace period allows a seamless transition when replacing sensors as well.
The iLet autonomous insulin delivery system streamlines diabetes management by reducing the burden on patients and physicians. It initially received FDA clearance in May 2023. iLet uses an adaptive, closed-loop algorithm that initializes with the user’s body weight and requires no additional insulin dosing parameters. The algorithm removes the need to manually adjust insulin pump therapy settings and variables.
Recent milestones include data on the use of the flagship iLet system in a “fully closed-loop” manner. The company also has effective formulary agreements in place with all major pharmacy benefit managers (PBMs) in the U.S. as of July. While the company continues to advance iLet, it also has the the “Mint” patch pump in development.
